Tailor Bio, a MedTech startup based in Cambridge, has been successful in leading a £650k grant  collaboration for the Innovate UK Biomedical Catalyst Award. 

Tailor was founded to improve precision medicine approaches for cancers with chromosomal  instability, a phenomenon present in over 80% of all cancers. 

Founded from research that originated from the Cancer Research UK Cambridge Institute, Tailor Bio is currently developing a pan-cancer precision medicine platform to produce new therapeutic and diagnostic approaches to improving patient care. 

Innovate UK, the UK’s innovation agency, funds business and research collaborations to accelerate  innovation and drive business investment into R&D. This is the second Innovate UK grant that Tailor  has received in support of the commercialisation of its technology platform and follows the successful development of a prototype as part of the Illumina Accelerator. 

The latest grant will allow Tailor Bio, along with collaborators Illumina and the University of Cambridge, to continue the development of a first diagnostic test to predict doxorubicin response in patients with high-grade serous ovarian cancer.  

Each year over 7,000 people are diagnosed with ovarian cancer in the UK. Many patients will be  prescribed doxorubicin, a common chemotherapy drug, even though approximately half of these  patients will actually benefit from the therapy. Tailor Bio’s doxorubicin test can help identify which  patients will not respond well to this common treatment, allowing patients to avoid potential toxic  side effects and the cost of ineffectual treatment. 

The project will evaluate the compatibility of Tailor’s technology with the Illumina TruSight Oncology  (TSO) Comprehensive (EU) assay, which has recently received CE-IVD certification in Europe and is  being implemented across the National Health Service. 

New tech launches to help children focus in class

“We’re delighted that Innovate UK continues to support the commercialisation of our technology,” said Jason Yip, CEO of Tailor Bio. 

“In addition to addressing an unmet need in ovarian cancer, Tailor’s doxorubicin test is a pivotal step for us to validate our precision medicine platform. 

“Stratifying patients away from ineffective treatment is beneficial, but the ultimate aim of Tailor Bio is to develop better therapeutic treatments for cancers with chromosomal instability.”

Walking app Follo raises £215k in VC funding